nodes	percent_of_prediction	percent_of_DWPC	metapath
Cyclobenzaprine—CYP3A4—Thiotepa—urinary bladder cancer	0.121	0.347	CbGbCtD
Cyclobenzaprine—CYP1A2—Fluorouracil—urinary bladder cancer	0.075	0.215	CbGbCtD
Cyclobenzaprine—CYP1A2—Etoposide—urinary bladder cancer	0.0626	0.179	CbGbCtD
Cyclobenzaprine—CYP2D6—Doxorubicin—urinary bladder cancer	0.0352	0.101	CbGbCtD
Cyclobenzaprine—CYP3A4—Etoposide—urinary bladder cancer	0.0328	0.094	CbGbCtD
Cyclobenzaprine—CYP3A4—Doxorubicin—urinary bladder cancer	0.0224	0.0641	CbGbCtD
Cyclobenzaprine—Olopatadine—S100B—urinary bladder cancer	0.00867	0.48	CrCbGaD
Cyclobenzaprine—CYP2D6—Miscellaneous substrates—CYP4B1—urinary bladder cancer	0.00455	0.0429	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—urine—urinary bladder cancer	0.00455	0.201	CbGeAlD
Cyclobenzaprine—CYP1A2—Arylamine metabolism—NAT2—urinary bladder cancer	0.00447	0.0421	CbGpPWpGaD
Cyclobenzaprine—Benzphetamine—POR—urinary bladder cancer	0.0039	0.216	CrCbGaD
Cyclobenzaprine—CYP2D6—Fatty acids—CYP4B1—urinary bladder cancer	0.00381	0.0359	CbGpPWpGaD
Cyclobenzaprine—HTR2A—urine—urinary bladder cancer	0.00356	0.157	CbGeAlD
Cyclobenzaprine—Carbamazepine—UGT2B7—urinary bladder cancer	0.00335	0.185	CrCbGaD
Cyclobenzaprine—CYP3A4—urine—urinary bladder cancer	0.00329	0.145	CbGeAlD
Cyclobenzaprine—CYP2D6—urine—urinary bladder cancer	0.00324	0.143	CbGeAlD
Cyclobenzaprine—CYP2D6—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00323	0.0305	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.0031	0.0292	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00274	0.0258	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00262	0.0247	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Estrogen metabolism—UGT2B7—urinary bladder cancer	0.00239	0.0225	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00222	0.0209	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Tamoxifen metabolism—UGT2B7—urinary bladder cancer	0.00211	0.0199	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00195	0.0184	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Oxidation by Cytochrome P450—POR—urinary bladder cancer	0.00171	0.0162	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00168	0.0158	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Aflatoxin B1 metabolism—GSTM1—urinary bladder cancer	0.00151	0.0142	CbGpPWpGaD
Cyclobenzaprine—Tamoxifen—ESR2—urinary bladder cancer	0.00133	0.0736	CrCbGaD
Cyclobenzaprine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—CYP4B1—urinary bladder cancer	0.00129	0.0122	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00126	0.0118	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00124	0.0117	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Arachidonic acid metabolism—CYP4B1—urinary bladder cancer	0.00123	0.0116	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Estrogen metabolism—NQO1—urinary bladder cancer	0.0012	0.0113	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—renal system—urinary bladder cancer	0.00111	0.0491	CbGeAlD
Cyclobenzaprine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.00106	0.01	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.00105	0.0099	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.00102	0.0096	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Phase II conjugation—GSTZ1—urinary bladder cancer	0.001	0.00946	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Phase II conjugation—GSTO2—urinary bladder cancer	0.000952	0.00897	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Phase II conjugation—NAT1—urinary bladder cancer	0.000952	0.00897	CbGpPWpGaD
Cyclobenzaprine—HTR2A—epithelium—urinary bladder cancer	0.000938	0.0414	CbGeAlD
Cyclobenzaprine—CYP1A2—Estrogen Receptor Pathway—ESR1—urinary bladder cancer	0.000934	0.0088	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Estrogen metabolism—NQO1—urinary bladder cancer	0.000923	0.0087	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000917	0.00864	CbGpPWpGaD
Cyclobenzaprine—HTR2A—smooth muscle tissue—urinary bladder cancer	0.000904	0.0399	CbGeAlD
Cyclobenzaprine—CYP1A2—Phase II conjugation—UGT2B7—urinary bladder cancer	0.00087	0.0082	CbGpPWpGaD
Cyclobenzaprine—HTR2A—renal system—urinary bladder cancer	0.00087	0.0384	CbGeAlD
Cyclobenzaprine—CYP1A2—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000863	0.00813	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Cytochrome P450 - arranged by substrate type—CYP4B1—urinary bladder cancer	0.000822	0.00774	CbGpPWpGaD
Cyclobenzaprine—Tamoxifen—ESR1—urinary bladder cancer	0.000819	0.0453	CrCbGaD
Cyclobenzaprine—CYP3A4—Oxidation by Cytochrome P450—CYP4B1—urinary bladder cancer	0.000811	0.00764	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—renal system—urinary bladder cancer	0.000805	0.0355	CbGeAlD
Cyclobenzaprine—CYP2D6—renal system—urinary bladder cancer	0.000792	0.035	CbGeAlD
Cyclobenzaprine—Paraesthesia—Cisplatin—urinary bladder cancer	0.000731	0.00145	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Etoposide—urinary bladder cancer	0.000731	0.00145	CcSEcCtD
Cyclobenzaprine—Upper respiratory tract infection—Methotrexate—urinary bladder cancer	0.000731	0.00145	CcSEcCtD
Cyclobenzaprine—Tachycardia—Etoposide—urinary bladder cancer	0.000728	0.00145	CcSEcCtD
Cyclobenzaprine—Eosinophilia—Epirubicin—urinary bladder cancer	0.000728	0.00145	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Cisplatin—urinary bladder cancer	0.000726	0.00144	CcSEcCtD
Cyclobenzaprine—Erectile dysfunction—Methotrexate—urinary bladder cancer	0.000724	0.00144	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Etoposide—urinary bladder cancer	0.000721	0.00143	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Gemcitabine—urinary bladder cancer	0.00072	0.00143	CcSEcCtD
Cyclobenzaprine—Anorexia—Etoposide—urinary bladder cancer	0.000711	0.00141	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Thiotepa—urinary bladder cancer	0.000711	0.00141	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Cisplatin—urinary bladder cancer	0.000708	0.0014	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Fluorouracil—urinary bladder cancer	0.000708	0.0014	CcSEcCtD
Cyclobenzaprine—CYP3A4—Estrogen metabolism—GSTM1—urinary bladder cancer	0.000707	0.00666	CbGpPWpGaD
Cyclobenzaprine—Drowsiness—Methotrexate—urinary bladder cancer	0.000701	0.00139	CcSEcCtD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—HPGDS—urinary bladder cancer	0.0007	0.0066	CbGpPWpGaD
Cyclobenzaprine—Pancytopenia—Epirubicin—urinary bladder cancer	0.000699	0.00139	CcSEcCtD
Cyclobenzaprine—Hypotension—Etoposide—urinary bladder cancer	0.000697	0.00138	CcSEcCtD
Cyclobenzaprine—Gastritis—Doxorubicin—urinary bladder cancer	0.000697	0.00138	CcSEcCtD
Cyclobenzaprine—HTR2A—female reproductive system—urinary bladder cancer	0.000697	0.0307	CbGeAlD
Cyclobenzaprine—CYP2D6—Biological oxidations—GSTZ1—urinary bladder cancer	0.000693	0.00653	CbGpPWpGaD
Cyclobenzaprine—Dizziness—Thiotepa—urinary bladder cancer	0.000687	0.00136	CcSEcCtD
Cyclobenzaprine—Upper respiratory tract infection—Epirubicin—urinary bladder cancer	0.000684	0.00136	CcSEcCtD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000684	0.00644	CbGpPWpGaD
Cyclobenzaprine—Stomatitis—Methotrexate—urinary bladder cancer	0.000683	0.00136	CcSEcCtD
Cyclobenzaprine—Urticaria—Fluorouracil—urinary bladder cancer	0.000683	0.00135	CcSEcCtD
Cyclobenzaprine—Pollakiuria—Epirubicin—urinary bladder cancer	0.00068	0.00135	CcSEcCtD
Cyclobenzaprine—Eosinophilia—Doxorubicin—urinary bladder cancer	0.000674	0.00134	CcSEcCtD
Cyclobenzaprine—Sweating—Methotrexate—urinary bladder cancer	0.000672	0.00133	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Cisplatin—urinary bladder cancer	0.000671	0.00133	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Etoposide—urinary bladder cancer	0.00067	0.00133	CcSEcCtD
Cyclobenzaprine—Weight increased—Epirubicin—urinary bladder cancer	0.000669	0.00133	CcSEcCtD
Cyclobenzaprine—CYP3A4—Phase 1 - Functionalization of compounds—CYP4B1—urinary bladder cancer	0.000666	0.00627	CbGpPWpGaD
Cyclobenzaprine—Dyspnoea—Etoposide—urinary bladder cancer	0.000665	0.00132	CcSEcCtD
Cyclobenzaprine—CYP3A4—Constitutive Androstane Receptor Pathway—SMC1A—urinary bladder cancer	0.000663	0.00625	CbGpPWpGaD
Cyclobenzaprine—Somnolence—Etoposide—urinary bladder cancer	0.000663	0.00132	CcSEcCtD
Cyclobenzaprine—Vomiting—Thiotepa—urinary bladder cancer	0.000661	0.00131	CcSEcCtD
Cyclobenzaprine—CYP2D6—Biological oxidations—GSTO2—urinary bladder cancer	0.000657	0.00619	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—NAT1—urinary bladder cancer	0.000657	0.00619	CbGpPWpGaD
Cyclobenzaprine—Drowsiness—Epirubicin—urinary bladder cancer	0.000656	0.0013	CcSEcCtD
Cyclobenzaprine—CYP1A2—Arachidonic acid metabolism—HPGDS—urinary bladder cancer	0.000655	0.00617	CbGpPWpGaD
Cyclobenzaprine—Rash—Thiotepa—urinary bladder cancer	0.000655	0.0013	CcSEcCtD
Cyclobenzaprine—Dermatitis—Thiotepa—urinary bladder cancer	0.000654	0.0013	CcSEcCtD
Cyclobenzaprine—Agranulocytosis—Methotrexate—urinary bladder cancer	0.000654	0.0013	CcSEcCtD
Cyclobenzaprine—Headache—Thiotepa—urinary bladder cancer	0.000651	0.00129	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Etoposide—urinary bladder cancer	0.000649	0.00129	CcSEcCtD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000648	0.00611	CbGpPWpGaD
Cyclobenzaprine—Pancytopenia—Doxorubicin—urinary bladder cancer	0.000646	0.00128	CcSEcCtD
Cyclobenzaprine—CYP3A4—female reproductive system—urinary bladder cancer	0.000645	0.0285	CbGeAlD
Cyclobenzaprine—Fatigue—Etoposide—urinary bladder cancer	0.000643	0.00128	CcSEcCtD
Cyclobenzaprine—Neuropathy peripheral—Epirubicin—urinary bladder cancer	0.000643	0.00128	CcSEcCtD
Cyclobenzaprine—Stomatitis—Epirubicin—urinary bladder cancer	0.000639	0.00127	CcSEcCtD
Cyclobenzaprine—Jaundice—Epirubicin—urinary bladder cancer	0.000639	0.00127	CcSEcCtD
Cyclobenzaprine—Constipation—Etoposide—urinary bladder cancer	0.000638	0.00127	CcSEcCtD
Cyclobenzaprine—CYP2D6—female reproductive system—urinary bladder cancer	0.000635	0.028	CbGeAlD
Cyclobenzaprine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—KRAS—urinary bladder cancer	0.000633	0.00597	CbGpPWpGaD
Cyclobenzaprine—Hypersensitivity—Fluorouracil—urinary bladder cancer	0.000633	0.00126	CcSEcCtD
Cyclobenzaprine—Upper respiratory tract infection—Doxorubicin—urinary bladder cancer	0.000633	0.00126	CcSEcCtD
Cyclobenzaprine—HTR2A—vagina—urinary bladder cancer	0.00063	0.0278	CbGeAlD
Cyclobenzaprine—Hepatitis—Methotrexate—urinary bladder cancer	0.000629	0.00125	CcSEcCtD
Cyclobenzaprine—Sweating—Epirubicin—urinary bladder cancer	0.000629	0.00125	CcSEcCtD
Cyclobenzaprine—Pollakiuria—Doxorubicin—urinary bladder cancer	0.000629	0.00125	CcSEcCtD
Cyclobenzaprine—Asthenia—Gemcitabine—urinary bladder cancer	0.000627	0.00124	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Methotrexate—urinary bladder cancer	0.000624	0.00124	CcSEcCtD
Cyclobenzaprine—Weight increased—Doxorubicin—urinary bladder cancer	0.000619	0.00123	CcSEcCtD
Cyclobenzaprine—Pruritus—Gemcitabine—urinary bladder cancer	0.000618	0.00123	CcSEcCtD
Cyclobenzaprine—Nausea—Thiotepa—urinary bladder cancer	0.000617	0.00122	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Etoposide—urinary bladder cancer	0.000615	0.00122	CcSEcCtD
Cyclobenzaprine—Agranulocytosis—Epirubicin—urinary bladder cancer	0.000612	0.00121	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Etoposide—urinary bladder cancer	0.00061	0.00121	CcSEcCtD
Cyclobenzaprine—Pruritus—Fluorouracil—urinary bladder cancer	0.000608	0.00121	CcSEcCtD
Cyclobenzaprine—Drowsiness—Doxorubicin—urinary bladder cancer	0.000607	0.0012	CcSEcCtD
Cyclobenzaprine—CYP2D6—Biological oxidations—UGT2B7—urinary bladder cancer	0.000601	0.00566	CbGpPWpGaD
Cyclobenzaprine—Hypersensitivity—Cisplatin—urinary bladder cancer	0.0006	0.00119	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Gemcitabine—urinary bladder cancer	0.000598	0.00119	CcSEcCtD
Cyclobenzaprine—Neuropathy peripheral—Doxorubicin—urinary bladder cancer	0.000595	0.00118	CcSEcCtD
Cyclobenzaprine—Urticaria—Etoposide—urinary bladder cancer	0.000593	0.00118	CcSEcCtD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000593	0.00558	CbGpPWpGaD
Cyclobenzaprine—Stomatitis—Doxorubicin—urinary bladder cancer	0.000592	0.00117	CcSEcCtD
Cyclobenzaprine—Jaundice—Doxorubicin—urinary bladder cancer	0.000592	0.00117	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Etoposide—urinary bladder cancer	0.00059	0.00117	CcSEcCtD
Cyclobenzaprine—Hepatitis—Epirubicin—urinary bladder cancer	0.000589	0.00117	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Fluorouracil—urinary bladder cancer	0.000588	0.00117	CcSEcCtD
Cyclobenzaprine—CYP1A2—Biological oxidations—GSTZ1—urinary bladder cancer	0.000587	0.00553	CbGpPWpGaD
Cyclobenzaprine—Tinnitus—Methotrexate—urinary bladder cancer	0.000587	0.00116	CcSEcCtD
Cyclobenzaprine—Hypoaesthesia—Epirubicin—urinary bladder cancer	0.000586	0.00116	CcSEcCtD
Cyclobenzaprine—Asthenia—Cisplatin—urinary bladder cancer	0.000584	0.00116	CcSEcCtD
Cyclobenzaprine—Pharyngitis—Epirubicin—urinary bladder cancer	0.000584	0.00116	CcSEcCtD
Cyclobenzaprine—Sweating—Doxorubicin—urinary bladder cancer	0.000582	0.00115	CcSEcCtD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000579	0.00546	CbGpPWpGaD
Cyclobenzaprine—Dizziness—Fluorouracil—urinary bladder cancer	0.000568	0.00113	CcSEcCtD
Cyclobenzaprine—Agranulocytosis—Doxorubicin—urinary bladder cancer	0.000566	0.00112	CcSEcCtD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—NQO1—urinary bladder cancer	0.000565	0.00532	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—NQO1—urinary bladder cancer	0.000565	0.00532	CbGpPWpGaD
Cyclobenzaprine—Diarrhoea—Cisplatin—urinary bladder cancer	0.000557	0.00111	CcSEcCtD
Cyclobenzaprine—CYP1A2—Biological oxidations—GSTO2—urinary bladder cancer	0.000557	0.00524	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—NAT1—urinary bladder cancer	0.000557	0.00524	CbGpPWpGaD
Cyclobenzaprine—Alopecia—Methotrexate—urinary bladder cancer	0.000556	0.0011	CcSEcCtD
Cyclobenzaprine—Vomiting—Gemcitabine—urinary bladder cancer	0.000556	0.0011	CcSEcCtD
Cyclobenzaprine—Rash—Gemcitabine—urinary bladder cancer	0.000551	0.00109	CcSEcCtD
Cyclobenzaprine—Dermatitis—Gemcitabine—urinary bladder cancer	0.000551	0.00109	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Etoposide—urinary bladder cancer	0.00055	0.00109	CcSEcCtD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000549	0.00517	CbGpPWpGaD
Cyclobenzaprine—Tinnitus—Epirubicin—urinary bladder cancer	0.000549	0.00109	CcSEcCtD
Cyclobenzaprine—Headache—Gemcitabine—urinary bladder cancer	0.000547	0.00109	CcSEcCtD
Cyclobenzaprine—Vomiting—Fluorouracil—urinary bladder cancer	0.000546	0.00108	CcSEcCtD
Cyclobenzaprine—Hepatitis—Doxorubicin—urinary bladder cancer	0.000545	0.00108	CcSEcCtD
Cyclobenzaprine—Hypoaesthesia—Doxorubicin—urinary bladder cancer	0.000542	0.00108	CcSEcCtD
Cyclobenzaprine—Rash—Fluorouracil—urinary bladder cancer	0.000542	0.00107	CcSEcCtD
Cyclobenzaprine—Dermatitis—Fluorouracil—urinary bladder cancer	0.000541	0.00107	CcSEcCtD
Cyclobenzaprine—CYP2D6—Biological oxidations—CYP4B1—urinary bladder cancer	0.000541	0.0051	CbGpPWpGaD
Cyclobenzaprine—Pharyngitis—Doxorubicin—urinary bladder cancer	0.000541	0.00107	CcSEcCtD
Cyclobenzaprine—HTR2A—Serotonin Receptor 2 and ELK-SRF/GATA4 signaling—HRAS—urinary bladder cancer	0.000538	0.00507	CbGpPWpGaD
Cyclobenzaprine—Headache—Fluorouracil—urinary bladder cancer	0.000538	0.00107	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Methotrexate—urinary bladder cancer	0.000536	0.00106	CcSEcCtD
Cyclobenzaprine—Asthenia—Etoposide—urinary bladder cancer	0.000535	0.00106	CcSEcCtD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000534	0.00503	CbGpPWpGaD
Cyclobenzaprine—Pruritus—Etoposide—urinary bladder cancer	0.000528	0.00105	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Epirubicin—urinary bladder cancer	0.000526	0.00104	CcSEcCtD
Cyclobenzaprine—CYP1A2—Phase II conjugation—NAT2—urinary bladder cancer	0.000521	0.00491	CbGpPWpGaD
Cyclobenzaprine—Alopecia—Epirubicin—urinary bladder cancer	0.00052	0.00103	CcSEcCtD
Cyclobenzaprine—Nausea—Gemcitabine—urinary bladder cancer	0.000519	0.00103	CcSEcCtD
Cyclobenzaprine—Vomiting—Cisplatin—urinary bladder cancer	0.000518	0.00103	CcSEcCtD
Cyclobenzaprine—Vision blurred—Methotrexate—urinary bladder cancer	0.000516	0.00102	CcSEcCtD
Cyclobenzaprine—Rash—Cisplatin—urinary bladder cancer	0.000514	0.00102	CcSEcCtD
Cyclobenzaprine—Dermatitis—Cisplatin—urinary bladder cancer	0.000513	0.00102	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Etoposide—urinary bladder cancer	0.000511	0.00101	CcSEcCtD
Cyclobenzaprine—Nausea—Fluorouracil—urinary bladder cancer	0.00051	0.00101	CcSEcCtD
Cyclobenzaprine—CYP1A2—Biological oxidations—UGT2B7—urinary bladder cancer	0.000509	0.0048	CbGpPWpGaD
Cyclobenzaprine—Ill-defined disorder—Methotrexate—urinary bladder cancer	0.000508	0.00101	CcSEcCtD
Cyclobenzaprine—Tinnitus—Doxorubicin—urinary bladder cancer	0.000508	0.00101	CcSEcCtD
Cyclobenzaprine—Flatulence—Epirubicin—urinary bladder cancer	0.000505	0.001	CcSEcCtD
Cyclobenzaprine—Tension—Epirubicin—urinary bladder cancer	0.000503	0.000998	CcSEcCtD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000502	0.00473	CbGpPWpGaD
Cyclobenzaprine—Dysgeusia—Epirubicin—urinary bladder cancer	0.000502	0.000996	CcSEcCtD
Cyclobenzaprine—Nervousness—Epirubicin—urinary bladder cancer	0.000498	0.000988	CcSEcCtD
Cyclobenzaprine—Malaise—Methotrexate—urinary bladder cancer	0.000494	0.00098	CcSEcCtD
Cyclobenzaprine—Dizziness—Etoposide—urinary bladder cancer	0.000493	0.000979	CcSEcCtD
Cyclobenzaprine—Vertigo—Methotrexate—urinary bladder cancer	0.000492	0.000976	CcSEcCtD
Cyclobenzaprine—Leukopenia—Methotrexate—urinary bladder cancer	0.00049	0.000973	CcSEcCtD
Cyclobenzaprine—Arrhythmia—Doxorubicin—urinary bladder cancer	0.000487	0.000966	CcSEcCtD
Cyclobenzaprine—Nausea—Cisplatin—urinary bladder cancer	0.000484	0.00096	CcSEcCtD
Cyclobenzaprine—Vision blurred—Epirubicin—urinary bladder cancer	0.000483	0.000958	CcSEcCtD
Cyclobenzaprine—Alopecia—Doxorubicin—urinary bladder cancer	0.000481	0.000955	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Epirubicin—urinary bladder cancer	0.000476	0.000944	CcSEcCtD
Cyclobenzaprine—Convulsion—Methotrexate—urinary bladder cancer	0.000475	0.000942	CcSEcCtD
Cyclobenzaprine—Vomiting—Etoposide—urinary bladder cancer	0.000474	0.000941	CcSEcCtD
Cyclobenzaprine—Agitation—Epirubicin—urinary bladder cancer	0.000471	0.000935	CcSEcCtD
Cyclobenzaprine—Rash—Etoposide—urinary bladder cancer	0.000471	0.000934	CcSEcCtD
Cyclobenzaprine—Dermatitis—Etoposide—urinary bladder cancer	0.00047	0.000933	CcSEcCtD
Cyclobenzaprine—Headache—Etoposide—urinary bladder cancer	0.000468	0.000928	CcSEcCtD
Cyclobenzaprine—Flatulence—Doxorubicin—urinary bladder cancer	0.000467	0.000927	CcSEcCtD
Cyclobenzaprine—Chest pain—Methotrexate—urinary bladder cancer	0.000466	0.000925	CcSEcCtD
Cyclobenzaprine—Myalgia—Methotrexate—urinary bladder cancer	0.000466	0.000925	CcSEcCtD
Cyclobenzaprine—Tension—Doxorubicin—urinary bladder cancer	0.000465	0.000923	CcSEcCtD
Cyclobenzaprine—Dysgeusia—Doxorubicin—urinary bladder cancer	0.000464	0.000921	CcSEcCtD
Cyclobenzaprine—Malaise—Epirubicin—urinary bladder cancer	0.000462	0.000917	CcSEcCtD
Cyclobenzaprine—Discomfort—Methotrexate—urinary bladder cancer	0.000461	0.000914	CcSEcCtD
Cyclobenzaprine—Nervousness—Doxorubicin—urinary bladder cancer	0.000461	0.000914	CcSEcCtD
Cyclobenzaprine—Vertigo—Epirubicin—urinary bladder cancer	0.000461	0.000914	CcSEcCtD
Cyclobenzaprine—Syncope—Epirubicin—urinary bladder cancer	0.00046	0.000912	CcSEcCtD
Cyclobenzaprine—Leukopenia—Epirubicin—urinary bladder cancer	0.000459	0.00091	CcSEcCtD
Cyclobenzaprine—CYP1A2—Biological oxidations—CYP4B1—urinary bladder cancer	0.000458	0.00432	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—GSTZ1—urinary bladder cancer	0.000453	0.00427	CbGpPWpGaD
Cyclobenzaprine—Palpitations—Epirubicin—urinary bladder cancer	0.000453	0.000899	CcSEcCtD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000452	0.00426	CbGpPWpGaD
Cyclobenzaprine—Confusional state—Methotrexate—urinary bladder cancer	0.000451	0.000894	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Epirubicin—urinary bladder cancer	0.000451	0.000894	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Methotrexate—urinary bladder cancer	0.000447	0.000887	CcSEcCtD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—GSTZ1—urinary bladder cancer	0.000447	0.00421	CbGpPWpGaD
Cyclobenzaprine—Vision blurred—Doxorubicin—urinary bladder cancer	0.000447	0.000887	CcSEcCtD
Cyclobenzaprine—Convulsion—Epirubicin—urinary bladder cancer	0.000444	0.000881	CcSEcCtD
Cyclobenzaprine—Nausea—Etoposide—urinary bladder cancer	0.000443	0.000879	CcSEcCtD
Cyclobenzaprine—Hypertension—Epirubicin—urinary bladder cancer	0.000443	0.000878	CcSEcCtD
Cyclobenzaprine—Ill-defined disorder—Doxorubicin—urinary bladder cancer	0.00044	0.000873	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Methotrexate—urinary bladder cancer	0.000438	0.000868	CcSEcCtD
Cyclobenzaprine—Myalgia—Epirubicin—urinary bladder cancer	0.000436	0.000866	CcSEcCtD
Cyclobenzaprine—Chest pain—Epirubicin—urinary bladder cancer	0.000436	0.000866	CcSEcCtD
Cyclobenzaprine—Agitation—Doxorubicin—urinary bladder cancer	0.000436	0.000865	CcSEcCtD
Cyclobenzaprine—Anxiety—Epirubicin—urinary bladder cancer	0.000435	0.000863	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Methotrexate—urinary bladder cancer	0.000432	0.000857	CcSEcCtD
Cyclobenzaprine—Discomfort—Epirubicin—urinary bladder cancer	0.000431	0.000855	CcSEcCtD
Cyclobenzaprine—CYP3A4—Biological oxidations—GSTO2—urinary bladder cancer	0.00043	0.00405	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—NAT1—urinary bladder cancer	0.00043	0.00405	CbGpPWpGaD
Cyclobenzaprine—Malaise—Doxorubicin—urinary bladder cancer	0.000428	0.000849	CcSEcCtD
Cyclobenzaprine—Dry mouth—Epirubicin—urinary bladder cancer	0.000427	0.000847	CcSEcCtD
Cyclobenzaprine—Vertigo—Doxorubicin—urinary bladder cancer	0.000426	0.000845	CcSEcCtD
Cyclobenzaprine—Anorexia—Methotrexate—urinary bladder cancer	0.000426	0.000845	CcSEcCtD
Cyclobenzaprine—Syncope—Doxorubicin—urinary bladder cancer	0.000425	0.000844	CcSEcCtD
Cyclobenzaprine—Leukopenia—Doxorubicin—urinary bladder cancer	0.000425	0.000842	CcSEcCtD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—GSTO2—urinary bladder cancer	0.000424	0.00399	CbGpPWpGaD
Cyclobenzaprine—Confusional state—Epirubicin—urinary bladder cancer	0.000422	0.000837	CcSEcCtD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—ESR2—urinary bladder cancer	0.00042	0.00396	CbGpPWpGaD
Cyclobenzaprine—Palpitations—Doxorubicin—urinary bladder cancer	0.000419	0.000832	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Epirubicin—urinary bladder cancer	0.000418	0.00083	CcSEcCtD
Cyclobenzaprine—Oedema—Epirubicin—urinary bladder cancer	0.000418	0.00083	CcSEcCtD
Cyclobenzaprine—Hypotension—Methotrexate—urinary bladder cancer	0.000418	0.000829	CcSEcCtD
Cyclobenzaprine—Loss of consciousness—Doxorubicin—urinary bladder cancer	0.000417	0.000827	CcSEcCtD
Cyclobenzaprine—CYP1A2—Phase II conjugation—HPGDS—urinary bladder cancer	0.000417	0.00393	CbGpPWpGaD
Cyclobenzaprine—Shock—Epirubicin—urinary bladder cancer	0.000412	0.000817	CcSEcCtD
Cyclobenzaprine—Convulsion—Doxorubicin—urinary bladder cancer	0.000411	0.000815	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Epirubicin—urinary bladder cancer	0.00041	0.000813	CcSEcCtD
Cyclobenzaprine—Hypertension—Doxorubicin—urinary bladder cancer	0.000409	0.000812	CcSEcCtD
Cyclobenzaprine—Tachycardia—Epirubicin—urinary bladder cancer	0.000408	0.00081	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Methotrexate—urinary bladder cancer	0.000407	0.000808	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Epirubicin—urinary bladder cancer	0.000404	0.000802	CcSEcCtD
Cyclobenzaprine—Insomnia—Methotrexate—urinary bladder cancer	0.000404	0.000802	CcSEcCtD
Cyclobenzaprine—CYP1A2—Phase II conjugation—GSTT1—urinary bladder cancer	0.000404	0.00381	CbGpPWpGaD
Cyclobenzaprine—Myalgia—Doxorubicin—urinary bladder cancer	0.000404	0.000801	CcSEcCtD
Cyclobenzaprine—Chest pain—Doxorubicin—urinary bladder cancer	0.000404	0.000801	CcSEcCtD
Cyclobenzaprine—Anxiety—Doxorubicin—urinary bladder cancer	0.000402	0.000798	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Methotrexate—urinary bladder cancer	0.000401	0.000796	CcSEcCtD
Cyclobenzaprine—Discomfort—Doxorubicin—urinary bladder cancer	0.000399	0.000791	CcSEcCtD
Cyclobenzaprine—Anorexia—Epirubicin—urinary bladder cancer	0.000399	0.000791	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Methotrexate—urinary bladder cancer	0.000399	0.000791	CcSEcCtD
Cyclobenzaprine—Somnolence—Methotrexate—urinary bladder cancer	0.000397	0.000788	CcSEcCtD
Cyclobenzaprine—CYP1A2—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000395	0.00372	CbGpPWpGaD
Cyclobenzaprine—Dry mouth—Doxorubicin—urinary bladder cancer	0.000395	0.000783	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Methotrexate—urinary bladder cancer	0.000393	0.000781	CcSEcCtD
Cyclobenzaprine—CYP3A4—Biological oxidations—UGT2B7—urinary bladder cancer	0.000393	0.0037	CbGpPWpGaD
Cyclobenzaprine—Hypotension—Epirubicin—urinary bladder cancer	0.000391	0.000776	CcSEcCtD
Cyclobenzaprine—Confusional state—Doxorubicin—urinary bladder cancer	0.00039	0.000774	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Methotrexate—urinary bladder cancer	0.000389	0.000771	CcSEcCtD
Cyclobenzaprine—CYP1A2—Arachidonic acid metabolism—GPX1—urinary bladder cancer	0.000388	0.00365	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—UGT2B7—urinary bladder cancer	0.000388	0.00365	CbGpPWpGaD
Cyclobenzaprine—Oedema—Doxorubicin—urinary bladder cancer	0.000387	0.000768	CcSEcCtD
Cyclobenzaprine—Anaphylactic shock—Doxorubicin—urinary bladder cancer	0.000387	0.000768	CcSEcCtD
Cyclobenzaprine—Fatigue—Methotrexate—urinary bladder cancer	0.000385	0.000765	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Epirubicin—urinary bladder cancer	0.000381	0.000756	CcSEcCtD
Cyclobenzaprine—Shock—Doxorubicin—urinary bladder cancer	0.000381	0.000756	CcSEcCtD
Cyclobenzaprine—Thrombocytopenia—Doxorubicin—urinary bladder cancer	0.000379	0.000752	CcSEcCtD
Cyclobenzaprine—Insomnia—Epirubicin—urinary bladder cancer	0.000378	0.000751	CcSEcCtD
Cyclobenzaprine—Tachycardia—Doxorubicin—urinary bladder cancer	0.000378	0.000749	CcSEcCtD
Cyclobenzaprine—Paraesthesia—Epirubicin—urinary bladder cancer	0.000376	0.000745	CcSEcCtD
Cyclobenzaprine—Hyperhidrosis—Doxorubicin—urinary bladder cancer	0.000374	0.000742	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Epirubicin—urinary bladder cancer	0.000373	0.00074	CcSEcCtD
Cyclobenzaprine—Somnolence—Epirubicin—urinary bladder cancer	0.000372	0.000738	CcSEcCtD
Cyclobenzaprine—Anorexia—Doxorubicin—urinary bladder cancer	0.000369	0.000732	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Methotrexate—urinary bladder cancer	0.000368	0.000731	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Epirubicin—urinary bladder cancer	0.000368	0.000731	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Methotrexate—urinary bladder cancer	0.000366	0.000725	CcSEcCtD
Cyclobenzaprine—Decreased appetite—Epirubicin—urinary bladder cancer	0.000364	0.000721	CcSEcCtD
Cyclobenzaprine—Hypotension—Doxorubicin—urinary bladder cancer	0.000362	0.000718	CcSEcCtD
Cyclobenzaprine—Fatigue—Epirubicin—urinary bladder cancer	0.000361	0.000716	CcSEcCtD
Cyclobenzaprine—CYP2D6—Biological oxidations—NAT2—urinary bladder cancer	0.00036	0.00339	CbGpPWpGaD
Cyclobenzaprine—Constipation—Epirubicin—urinary bladder cancer	0.000358	0.00071	CcSEcCtD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000355	0.00335	CbGpPWpGaD
Cyclobenzaprine—Urticaria—Methotrexate—urinary bladder cancer	0.000355	0.000705	CcSEcCtD
Cyclobenzaprine—CYP3A4—Biological oxidations—CYP4B1—urinary bladder cancer	0.000354	0.00333	CbGpPWpGaD
Cyclobenzaprine—Abdominal pain—Methotrexate—urinary bladder cancer	0.000353	0.000701	CcSEcCtD
Cyclobenzaprine—Musculoskeletal discomfort—Doxorubicin—urinary bladder cancer	0.000353	0.0007	CcSEcCtD
Cyclobenzaprine—Insomnia—Doxorubicin—urinary bladder cancer	0.00035	0.000695	CcSEcCtD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—CYP4B1—urinary bladder cancer	0.000349	0.00329	CbGpPWpGaD
Cyclobenzaprine—Paraesthesia—Doxorubicin—urinary bladder cancer	0.000348	0.00069	CcSEcCtD
Cyclobenzaprine—Dyspnoea—Doxorubicin—urinary bladder cancer	0.000345	0.000685	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Epirubicin—urinary bladder cancer	0.000345	0.000684	CcSEcCtD
Cyclobenzaprine—Somnolence—Doxorubicin—urinary bladder cancer	0.000344	0.000683	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Epirubicin—urinary bladder cancer	0.000342	0.000679	CcSEcCtD
Cyclobenzaprine—Dyspepsia—Doxorubicin—urinary bladder cancer	0.000341	0.000676	CcSEcCtD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—ESR1—urinary bladder cancer	0.00034	0.0032	CbGpPWpGaD
Cyclobenzaprine—Decreased appetite—Doxorubicin—urinary bladder cancer	0.000336	0.000668	CcSEcCtD
Cyclobenzaprine—Fatigue—Doxorubicin—urinary bladder cancer	0.000334	0.000662	CcSEcCtD
Cyclobenzaprine—Urticaria—Epirubicin—urinary bladder cancer	0.000332	0.000659	CcSEcCtD
Cyclobenzaprine—Constipation—Doxorubicin—urinary bladder cancer	0.000331	0.000657	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Epirubicin—urinary bladder cancer	0.000331	0.000656	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Methotrexate—urinary bladder cancer	0.000329	0.000653	CcSEcCtD
Cyclobenzaprine—Asthenia—Methotrexate—urinary bladder cancer	0.000321	0.000636	CcSEcCtD
Cyclobenzaprine—Feeling abnormal—Doxorubicin—urinary bladder cancer	0.000319	0.000633	CcSEcCtD
Cyclobenzaprine—Gastrointestinal pain—Doxorubicin—urinary bladder cancer	0.000317	0.000628	CcSEcCtD
Cyclobenzaprine—Pruritus—Methotrexate—urinary bladder cancer	0.000316	0.000627	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Epirubicin—urinary bladder cancer	0.000308	0.000611	CcSEcCtD
Cyclobenzaprine—Urticaria—Doxorubicin—urinary bladder cancer	0.000307	0.00061	CcSEcCtD
Cyclobenzaprine—Abdominal pain—Doxorubicin—urinary bladder cancer	0.000306	0.000607	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Methotrexate—urinary bladder cancer	0.000306	0.000607	CcSEcCtD
Cyclobenzaprine—CYP1A2—Biological oxidations—NAT2—urinary bladder cancer	0.000305	0.00287	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Nuclear Receptors in Lipid Metabolism and Toxicity—PPARG—urinary bladder cancer	0.000305	0.00287	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000301	0.00283	CbGpPWpGaD
Cyclobenzaprine—Asthenia—Epirubicin—urinary bladder cancer	0.0003	0.000595	CcSEcCtD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—RB1—urinary bladder cancer	0.000297	0.0028	CbGpPWpGaD
Cyclobenzaprine—Pruritus—Epirubicin—urinary bladder cancer	0.000296	0.000587	CcSEcCtD
Cyclobenzaprine—Dizziness—Methotrexate—urinary bladder cancer	0.000296	0.000586	CcSEcCtD
Cyclobenzaprine—CYP2D6—Biological oxidations—HPGDS—urinary bladder cancer	0.000288	0.00271	CbGpPWpGaD
Cyclobenzaprine—Diarrhoea—Epirubicin—urinary bladder cancer	0.000286	0.000568	CcSEcCtD
Cyclobenzaprine—Hypersensitivity—Doxorubicin—urinary bladder cancer	0.000285	0.000566	CcSEcCtD
Cyclobenzaprine—Vomiting—Methotrexate—urinary bladder cancer	0.000284	0.000564	CcSEcCtD
Cyclobenzaprine—Rash—Methotrexate—urinary bladder cancer	0.000282	0.000559	CcSEcCtD
Cyclobenzaprine—Dermatitis—Methotrexate—urinary bladder cancer	0.000282	0.000559	CcSEcCtD
Cyclobenzaprine—CYP1A2—Phase II conjugation—GSTP1—urinary bladder cancer	0.00028	0.00264	CbGpPWpGaD
Cyclobenzaprine—Headache—Methotrexate—urinary bladder cancer	0.00028	0.000556	CcSEcCtD
Cyclobenzaprine—CYP2D6—Biological oxidations—GSTT1—urinary bladder cancer	0.000279	0.00263	CbGpPWpGaD
Cyclobenzaprine—Asthenia—Doxorubicin—urinary bladder cancer	0.000278	0.000551	CcSEcCtD
Cyclobenzaprine—Dizziness—Epirubicin—urinary bladder cancer	0.000277	0.000549	CcSEcCtD
Cyclobenzaprine—Pruritus—Doxorubicin—urinary bladder cancer	0.000274	0.000543	CcSEcCtD
Cyclobenzaprine—Vomiting—Epirubicin—urinary bladder cancer	0.000266	0.000528	CcSEcCtD
Cyclobenzaprine—Nausea—Methotrexate—urinary bladder cancer	0.000266	0.000527	CcSEcCtD
Cyclobenzaprine—Diarrhoea—Doxorubicin—urinary bladder cancer	0.000265	0.000525	CcSEcCtD
Cyclobenzaprine—Rash—Epirubicin—urinary bladder cancer	0.000264	0.000523	CcSEcCtD
Cyclobenzaprine—Dermatitis—Epirubicin—urinary bladder cancer	0.000264	0.000523	CcSEcCtD
Cyclobenzaprine—Headache—Epirubicin—urinary bladder cancer	0.000262	0.00052	CcSEcCtD
Cyclobenzaprine—CYP1A2—Phase II conjugation—GSTM1—urinary bladder cancer	0.000258	0.00243	CbGpPWpGaD
Cyclobenzaprine—Dizziness—Doxorubicin—urinary bladder cancer	0.000256	0.000508	CcSEcCtD
Cyclobenzaprine—Nausea—Epirubicin—urinary bladder cancer	0.000248	0.000493	CcSEcCtD
Cyclobenzaprine—Vomiting—Doxorubicin—urinary bladder cancer	0.000246	0.000488	CcSEcCtD
Cyclobenzaprine—Rash—Doxorubicin—urinary bladder cancer	0.000244	0.000484	CcSEcCtD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—PTGS2—urinary bladder cancer	0.000244	0.0023	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—HPGDS—urinary bladder cancer	0.000244	0.0023	CbGpPWpGaD
Cyclobenzaprine—Dermatitis—Doxorubicin—urinary bladder cancer	0.000244	0.000484	CcSEcCtD
Cyclobenzaprine—Headache—Doxorubicin—urinary bladder cancer	0.000242	0.000481	CcSEcCtD
Cyclobenzaprine—CYP1A2—Biological oxidations—GSTT1—urinary bladder cancer	0.000237	0.00223	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—NAT2—urinary bladder cancer	0.000235	0.00222	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—NAT2—urinary bladder cancer	0.000232	0.00219	CbGpPWpGaD
Cyclobenzaprine—Nausea—Doxorubicin—urinary bladder cancer	0.00023	0.000456	CcSEcCtD
Cyclobenzaprine—CYP1A2—Arachidonic acid metabolism—PTGS2—urinary bladder cancer	0.000228	0.00215	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—urinary bladder cancer	0.000226	0.00213	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—CREBBP—urinary bladder cancer	0.000223	0.0021	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—urinary bladder cancer	0.000213	0.00201	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EP300—urinary bladder cancer	0.000203	0.00191	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—EP300—urinary bladder cancer	0.000203	0.00191	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—SRC—urinary bladder cancer	0.000197	0.00186	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—SRC—urinary bladder cancer	0.000197	0.00186	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—GSTP1—urinary bladder cancer	0.000194	0.00182	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000191	0.0018	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—HPGDS—urinary bladder cancer	0.000188	0.00177	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—GSTT1—urinary bladder cancer	0.000183	0.00172	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Biological oxidations—GSTM1—urinary bladder cancer	0.000178	0.00168	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—CXCL8—urinary bladder cancer	0.000177	0.00167	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—MYC—urinary bladder cancer	0.000177	0.00167	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—CYP4B1—urinary bladder cancer	0.000176	0.00166	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000175	0.00165	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—EGFR—urinary bladder cancer	0.000173	0.00163	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—EGFR—urinary bladder cancer	0.000173	0.00163	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—urinary bladder cancer	0.000165	0.00155	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—urinary bladder cancer	0.000165	0.00155	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—GSTP1—urinary bladder cancer	0.000164	0.00154	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—KRAS—urinary bladder cancer	0.000163	0.00154	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000162	0.00152	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—EP300—urinary bladder cancer	0.000152	0.00143	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Biological oxidations—GSTM1—urinary bladder cancer	0.000151	0.00142	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000149	0.0014	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Aryl Hydrocarbon Receptor—HRAS—urinary bladder cancer	0.000139	0.00131	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—GSTP1—urinary bladder cancer	0.000127	0.00119	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—GSTP1—urinary bladder cancer	0.000125	0.00118	CbGpPWpGaD
Cyclobenzaprine—HTR2A—SIDS Susceptibility Pathways—TNF—urinary bladder cancer	0.000123	0.00116	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTZ1—urinary bladder cancer	0.000119	0.00112	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Biological oxidations—GSTM1—urinary bladder cancer	0.000116	0.0011	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metapathway biotransformation—GSTM1—urinary bladder cancer	0.000115	0.00108	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HDAC4—urinary bladder cancer	0.000115	0.00108	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTO2—urinary bladder cancer	0.000112	0.00106	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NAT1—urinary bladder cancer	0.000112	0.00106	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—UGT2B7—urinary bladder cancer	0.000103	0.000968	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL8—urinary bladder cancer	0.000102	0.000957	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTZ1—urinary bladder cancer	0.0001	0.000946	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—EGFR—urinary bladder cancer	0.0001	0.000945	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—GLI1—urinary bladder cancer	9.6e-05	0.000905	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTO2—urinary bladder cancer	9.52e-05	0.000897	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NAT1—urinary bladder cancer	9.52e-05	0.000897	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—KRAS—urinary bladder cancer	9.47e-05	0.000892	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—HPGDS—urinary bladder cancer	9.36e-05	0.000882	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CYP4B1—urinary bladder cancer	9.25e-05	0.000872	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—SLC19A1—urinary bladder cancer	8.74e-05	0.000823	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—UGT2B7—urinary bladder cancer	8.71e-05	0.00082	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PRSS3—urinary bladder cancer	8.52e-05	0.000802	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—HRAS—urinary bladder cancer	8.05e-05	0.000759	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CYP4B1—urinary bladder cancer	7.84e-05	0.000739	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTZ1—urinary bladder cancer	7.75e-05	0.00073	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR ligand binding—CXCL8—urinary bladder cancer	7.74e-05	0.000729	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—SLC19A1—urinary bladder cancer	7.4e-05	0.000698	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTO2—urinary bladder cancer	7.35e-05	0.000692	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NAT1—urinary bladder cancer	7.35e-05	0.000692	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PRSS3—urinary bladder cancer	7.22e-05	0.00068	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—TYMP—urinary bladder cancer	6.81e-05	0.000641	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—UGT2B7—urinary bladder cancer	6.72e-05	0.000633	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—RBX1—urinary bladder cancer	6.58e-05	0.00062	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TSC1—urinary bladder cancer	6.19e-05	0.000583	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NAT2—urinary bladder cancer	6.16e-05	0.00058	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CYP4B1—urinary bladder cancer	6.05e-05	0.00057	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—JAG1—urinary bladder cancer	5.89e-05	0.000555	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—NCOR1—urinary bladder cancer	5.78e-05	0.000545	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—TYMP—urinary bladder cancer	5.77e-05	0.000543	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—SLC19A1—urinary bladder cancer	5.71e-05	0.000538	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PRSS3—urinary bladder cancer	5.57e-05	0.000525	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—GPX1—urinary bladder cancer	5.54e-05	0.000522	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—RRM2—urinary bladder cancer	5.32e-05	0.000501	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NAT2—urinary bladder cancer	5.22e-05	0.000491	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—RHOA—urinary bladder cancer	4.98e-05	0.000469	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—HPGDS—urinary bladder cancer	4.92e-05	0.000464	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ENO2—urinary bladder cancer	4.92e-05	0.000464	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTT1—urinary bladder cancer	4.77e-05	0.00045	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—S100B—urinary bladder cancer	4.77e-05	0.000449	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—RHOA—urinary bladder cancer	4.52e-05	0.000426	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—RRM2—urinary bladder cancer	4.5e-05	0.000424	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—TYMP—urinary bladder cancer	4.45e-05	0.000419	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—CXCL8—urinary bladder cancer	4.37e-05	0.000412	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—NCOR1—urinary bladder cancer	4.29e-05	0.000404	CbGpPWpGaD
Cyclobenzaprine—HTR2A—GPCR downstream signaling—IL2—urinary bladder cancer	4.18e-05	0.000394	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—HPGDS—urinary bladder cancer	4.17e-05	0.000393	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ENO2—urinary bladder cancer	4.17e-05	0.000393	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PPARG—urinary bladder cancer	4.15e-05	0.000391	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTT1—urinary bladder cancer	4.04e-05	0.000381	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NAT2—urinary bladder cancer	4.03e-05	0.000379	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—CREBBP—urinary bladder cancer	3.98e-05	0.000375	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—CXCL8—urinary bladder cancer	3.97e-05	0.000374	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NQO1—urinary bladder cancer	3.97e-05	0.000374	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—IL2—urinary bladder cancer	3.79e-05	0.000357	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TERT—urinary bladder cancer	3.78e-05	0.000356	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—RRM2—urinary bladder cancer	3.48e-05	0.000327	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—FGFR3—urinary bladder cancer	3.47e-05	0.000327	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ESR1—urinary bladder cancer	3.37e-05	0.000317	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NQO1—urinary bladder cancer	3.36e-05	0.000317	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTP1—urinary bladder cancer	3.31e-05	0.000312	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PTGS2—urinary bladder cancer	3.26e-05	0.000307	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—HPGDS—urinary bladder cancer	3.22e-05	0.000303	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ENO2—urinary bladder cancer	3.22e-05	0.000303	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTT1—urinary bladder cancer	3.12e-05	0.000294	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—TYMS—urinary bladder cancer	3.08e-05	0.00029	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GSTM1—urinary bladder cancer	3.04e-05	0.000287	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—NCOR1—urinary bladder cancer	3.04e-05	0.000287	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CREBBP—urinary bladder cancer	2.95e-05	0.000278	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IGF1—urinary bladder cancer	2.92e-05	0.000275	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—GPX1—urinary bladder cancer	2.91e-05	0.000274	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—EGFR—urinary bladder cancer	2.9e-05	0.000273	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—ERCC2—urinary bladder cancer	2.86e-05	0.000269	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—urinary bladder cancer	2.84e-05	0.000268	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTP1—urinary bladder cancer	2.8e-05	0.000264	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—KRAS—urinary bladder cancer	2.74e-05	0.000258	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism of lipids and lipoproteins—EP300—urinary bladder cancer	2.71e-05	0.000256	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—MTHFR—urinary bladder cancer	2.69e-05	0.000253	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—RHOA—urinary bladder cancer	2.67e-05	0.000252	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—TYMS—urinary bladder cancer	2.61e-05	0.000246	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NQO1—urinary bladder cancer	2.59e-05	0.000244	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GSTM1—urinary bladder cancer	2.58e-05	0.000243	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—NCOR1—urinary bladder cancer	2.58e-05	0.000243	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—ERBB2—urinary bladder cancer	2.47e-05	0.000233	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—GPX1—urinary bladder cancer	2.47e-05	0.000232	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—ERCC2—urinary bladder cancer	2.42e-05	0.000228	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CXCL8—urinary bladder cancer	2.35e-05	0.000221	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling by GPCR—HRAS—urinary bladder cancer	2.33e-05	0.00022	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—MTHFR—urinary bladder cancer	2.28e-05	0.000215	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—IL2—urinary bladder cancer	2.24e-05	0.000211	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CCND1—urinary bladder cancer	2.18e-05	0.000206	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PPARG—urinary bladder cancer	2.18e-05	0.000205	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTP1—urinary bladder cancer	2.16e-05	0.000204	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MMP9—urinary bladder cancer	2.12e-05	0.0002	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—CDKN1A—urinary bladder cancer	2.11e-05	0.000199	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—PTEN—urinary bladder cancer	2.11e-05	0.000199	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—CREBBP—urinary bladder cancer	2.09e-05	0.000197	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—TYMS—urinary bladder cancer	2.01e-05	0.00019	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—EP300—urinary bladder cancer	2.01e-05	0.000189	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GSTM1—urinary bladder cancer	1.99e-05	0.000187	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—NCOR1—urinary bladder cancer	1.99e-05	0.000187	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—SRC—urinary bladder cancer	1.96e-05	0.000184	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—GPX1—urinary bladder cancer	1.9e-05	0.000179	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—ERCC2—urinary bladder cancer	1.87e-05	0.000176	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PPARG—urinary bladder cancer	1.85e-05	0.000174	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—CREBBP—urinary bladder cancer	1.77e-05	0.000167	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—MTHFR—urinary bladder cancer	1.76e-05	0.000166	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—MYC—urinary bladder cancer	1.75e-05	0.000165	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PTGS2—urinary bladder cancer	1.71e-05	0.000162	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—EGFR—urinary bladder cancer	1.71e-05	0.000161	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—KRAS—urinary bladder cancer	1.62e-05	0.000153	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—PTEN—urinary bladder cancer	1.5e-05	0.000141	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PTGS2—urinary bladder cancer	1.45e-05	0.000137	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—TP53—urinary bladder cancer	1.44e-05	0.000136	CbGpPWpGaD
Cyclobenzaprine—CYP2D6—Metabolism—EP300—urinary bladder cancer	1.43e-05	0.000134	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PPARG—urinary bladder cancer	1.42e-05	0.000134	CbGpPWpGaD
Cyclobenzaprine—HTR2A—Signaling Pathways—HRAS—urinary bladder cancer	1.38e-05	0.00013	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—CREBBP—urinary bladder cancer	1.37e-05	0.000129	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—PTEN—urinary bladder cancer	1.27e-05	0.000119	CbGpPWpGaD
Cyclobenzaprine—CYP1A2—Metabolism—EP300—urinary bladder cancer	1.21e-05	0.000114	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PTGS2—urinary bladder cancer	1.12e-05	0.000106	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—PTEN—urinary bladder cancer	9.78e-06	9.21e-05	CbGpPWpGaD
Cyclobenzaprine—CYP3A4—Metabolism—EP300—urinary bladder cancer	9.32e-06	8.78e-05	CbGpPWpGaD
